Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 3NETWORK 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia 5Myelodysplastic Syndromes 3Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma 2Leukemia, Biphenotypic, Acute 2Stomatitis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hodgkin Disease 1Congenital Abnormalities 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Imatinib Mesylate 8venetoclax 6Cytarabine 5ponatinib 4nilotinib 4Azacitidine 4zosuquidar trihydrochloride 2fludarabine 2bosutinib 2RO6839921 2Decitabine 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2spartalizumab 1sabatolimab 1pulrodemstat besilate 1posaconazole 1pegfilgrastim 1lestaurtinib 1gilteritinib 1flumatinib 1enasidenib 1emvododstat 1blinatumomab 1asciminib 1Whole-Body Irradiation 1N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide 1Lenalidomide 1Immunotherapy, Adoptive 1Idarubicin 1IMC-EB10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myeloid × Whole-Body Irradiation × Clear all
NCT07157514 2025-09-10

Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML

Actinium Pharmaceuticals

Phase 2/3 Not yet recruiting
306 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡